4574 TAIKO PHARMACEUTICAL CO., LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4574

TSE Prime

TAIKO PHARMACEUTICAL CO., LTD.

294

JPY

(+0.34%)

Dec 5, 12:54 pm JST

1.89

USD

Dec 4, 10:54 pm EST

Result

PTS

outside of trading hours

294.9

Dec 5, 10:44 am JST

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2021	11,299	-4,947	-6,131	-9,594	-220.5	0	Feb 18, 2022	J-GAAP
Dec, 2022	5,040	-3,079	-3,352	-4,895	-112.3	0	Feb 10, 2023	J-GAAP
Dec, 2023	6,120	-1,005	-1,248	-3,611	-76.3	0	Feb 9, 2024	J-GAAP
Dec, 2024	6,292	629	688	898	17.9	0	Feb 13, 2025	J-GAAP
Dec, 2025 Guidance	6,300	300	300	580	11.5	－	Nov 11, 2025	J-GAAP
YoY	+0.1%	-52.3%	-56.4%	-35.4%	-35.5%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 14, 2019	11,260	2,200	1,950	1,420	10	J-GAAP
	Feb 10, 2020	13,600	3,000	2,750	1,850	13.33	J-GAAP
Results	May 12, 2020	14,966	3,824	3,633	2,453	16.67	J-GAAP
Dec, 2020 Changed	May 12, 2020	13,500	3,700	3,500	2,500	17*	J-GAAP
Changed	Aug 12, 2020	18,000	5,500	5,300	3,800	17*	J-GAAP
Changed	Dec 18, 2020	18,000	5,500	5,300	3,800	25*	J-GAAP
Results Changed	Feb 12, 2021	17,582	5,650	5,454	3,851	25*	J-GAAP
Dec, 2021	Feb 12, 2021	Available in future release
	Aug 6, 2021
Results	Feb 18, 2022
Dec, 2022	Feb 18, 2022
	Aug 12, 2022
Results	Feb 10, 2023
Dec, 2023	Feb 10, 2023
	Nov 10, 2023
Results	Feb 9, 2024
Dec, 2024	Feb 9, 2024
	Mar 7, 2024
	Aug 9, 2024
Results	Feb 13, 2025
Dec, 2025	Feb 13, 2025	6,300	215	200	300	－	J-GAAP
-	Aug 20, 2025	6,300	215	200	450	－	J-GAAP
-	Nov 11, 2025	6,300	300	300	580	－	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct, 2004	4,713	－	Available in future release
Mar, 2005 Changed	1,609	－
Mar, 2006	5,065	+214.8
Mar, 2007	4,935	-2.6
Mar, 2008	5,540	+12.3
Mar, 2009	6,094	+10.0
Mar, 2010	8,816	+44.7
Mar, 2011	4,619	-47.6
Mar, 2012	6,683	+44.7
Mar, 2013	7,443	+11.4
Mar, 2014	9,947	+33.6
Mar, 2015	8,978	-9.7
Mar, 2016	8,327	-7.3
Mar, 2017	8,294	-0.4
Mar, 2018	9,459	+14.0
Mar, 2019	10,418	+10.1
Mar, 2020	14,966	+43.7
Dec, 2020 Changed	17,582	－
Dec, 2021	11,299	-35.7
Dec, 2022	5,040	-55.4
Dec, 2023	6,120	+21.4
Dec, 2024	6,292	+2.8
Dec, 2025 Guidance	6,300	+0.1	300	-52.3	300	-56.4	11.5	-35.8

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2023	6,120	-1,005	-16	-48.85	-25.55	0.43	-76.3
Dec, 2024	6,292	629	10.0	12.22	6.87	0.48	17.9
Dec, 2025 Guidance	6,300	300	4.76	7.04	4.88	0.53	11.5

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	14,966	3,824	3,633	2,453	57.6
Fiscal Year	Mar, 2020	Mar, 2020	Mar, 2020	Mar, 2020	Mar, 2020

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2022	3,183	-662	-837	-2,097	-48.1	0	Feb 10, 2023	J-GAAP
Jul - Dec, 2023	3,632	-609	-738	-3,097	-65.4	0	Feb 9, 2024	J-GAAP
Jul - Dec, 2024	3,432	147	160	134	2.7	0	Feb 13, 2025	J-GAAP
Jul - Dec, 2025 Guidance	3,888	254	280	301	6.0	－	Nov 11, 2025	J-GAAP
YoY	+13.3%	+72.8%	+75.0%	+124.6%	+124.3%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2022	-3,079	-1,804	-1,994	190	-997	2,797	18.59	J-GAAP
Dec, 2023	-1,005	859	-307	1,166	1,539	5,244	39.67	J-GAAP
Dec, 2024	629	357	362	-5	-1,181	4,532	35.09	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2023	4,417	-444	-589	-562	-12.1	ー	Nov 10, 2023	J-GAAP
Jan - Sep, 2024	4,579	726	705	714	14.2	102.5	Nov 8, 2024	J-GAAP
Jan - Sep, 2025	4,229	324	325	669	13.3	108.3	Nov 11, 2025	J-GAAP
YoY	-7.6%	-55.4%	-53.9%	-6.3%	-6.4%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	1,703	-561	-659	-3,049	-64.4	-32.9	Feb 9, 2024	J-GAAP
Jan - Mar, 2024	1,377	214	229	472	9.4	15.5	May 10, 2024	J-GAAP
Apr - Jun, 2024	1,483	268	299	292	5.8	18.1	Aug 9, 2024	J-GAAP
Jul - Sep, 2024	1,719	244	177	-50	-1.0	14.2	Nov 8, 2024	J-GAAP
Oct - Dec, 2024	1,713	-97	-17	184	3.7	-5.7	Feb 13, 2025	J-GAAP
Jan - Mar, 2025	1,150	44	11	292	5.8	3.8	May 9, 2025	J-GAAP
Apr - Jun, 2025	1,262	2	9	-13	-0.3	0.2	Aug 8, 2025	J-GAAP
Jul - Sep, 2025	1,817	278	305	390	7.8	15.3	Nov 11, 2025	J-GAAP
YoY	+5.7%	+13.9%	+72.3%	－	－

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	6,615	+15.9	Available in future release
Jan - Mar, 2021	3,271	－
Apr - Jun, 2021	1,835	－
Jul - Sep, 2021	3,249	－
Oct - Dec, 2021	2,944	－
Jan - Mar, 2022	621	-81.0
Apr - Jun, 2022	1,236	-32.6
Jul - Sep, 2022	1,532	-52.8
Oct - Dec, 2022	1,651	-43.9
Jan - Mar, 2023	1,167	+87.9
Apr - Jun, 2023	1,321	+6.9
Jul - Sep, 2023	1,929	+25.9
Oct - Dec, 2023	1,703	+3.1
Jan - Mar, 2024	1,377	+18.0
Apr - Jun, 2024	1,483	+12.3
Jul - Sep, 2024	1,719	-10.9
Oct - Dec, 2024	1,713	+0.6
Jan - Mar, 2025	1,150	-16.5
Apr - Jun, 2025	1,262	-14.9
Jul - Sep, 2025	1,817	+5.7	278	+13.9	305	+72.3	7.8	－

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	6,615	2,757	2,702	1,870	43.6
Fiscal Year	Dec, 2020	Jun, 2020	Jun, 2020	Jun, 2020	Jun, 2020

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2022	184.60	53.5	15,046	8,044	5,239	0.47	Feb 10, 2023	J-GAAP
Dec, 2023	134.93	51.0	13,220	6,739	1,628	0.48	Feb 9, 2024	J-GAAP
Dec, 2024	158.67	61.7	12,914	7,964	2,526	0.25	Feb 13, 2025	J-GAAP
Jan - Sep, 2025	ー	69.3	11,884	8,236	3,196	0.12	Nov 11, 2025	J-GAAP

TAIKO PHARMACEUTICAL CO., LTD.(4574) Financial Results